Cartesian Therapeutics
Stock Forecast, Prediction & Price Target
Cartesian Therapeutics Financial Estimates
Cartesian Therapeutics Revenue Estimates
Cartesian Therapeutics EBITDA Estimates
Cartesian Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $85.07M N/A | $110.77M 30.20% | $26.00M -76.52% | Avg: $12.29M Low: $7.95M High: $20.97M avg. -52.73% | Avg: $13.70M Low: $8.87M High: $23.38M avg. 11.50% | Avg: $56.2M Low: $36.39M High: $95.90M avg. 310.08% | Avg: $22.45M Low: $14.53M High: $38.31M avg. -60.05% |
Net Income
% change YoY
| $-25.68M N/A | $35.37M 237.73% | $-219.71M -721.01% | Avg: $-66.19M Low: $-56.24M High: $-12.33M avg. 69.86% | Avg: $-86.67M Low: $-26.36M High: $-12.33M avg. -30.92% | Avg: $-34.44M Low: $-66.08M High: $-18.66M avg. 60.25% | Avg: $-34.96M Low: $-67.07M High: $-18.94M avg. -1.49% |
EBITDA
% change YoY
| $-3.33M N/A | $16.15M 585.13% | $-235.06M -1555.05% | Avg: $-7.11M Low: $-12.13M High: $-4.60M avg. 96.97% | Avg: $-7.93M Low: $-13.53M High: $-5.13M avg. -11.50% | Avg: $-32.52M Low: $-55.49M High: $-21.05M avg. -310.08% | Avg: $-12.99M Low: $-22.17M High: $-8.41M avg. 60.05% |
EPS
% change YoY
| -$6.74 N/A | $7.33 208.75% | -$42.49 -679.67% | Avg: -$4.84 Low: -$10.9 High: -$2.39 avg. 88.62% | Avg: -$4.09 Low: -$5.11 High: -$2.39 avg. 15.33% | Avg: -$6.68 Low: -$12.81 High: -$3.62 avg. -63.07% | Avg: -$6.78 Low: -$13 High: -$3.67 avg. -1.49% |
Operating Expenses
% change YoY
| $89.67M N/A | $96.23M 7.32% | $110.86M 15.19% | Avg: $13.05M Low: $8.45M High: $22.28M avg. -88.22% | Avg: $14.56M Low: $9.42M High: $24.85M avg. 11.50% | Avg: $59.71M Low: $38.66M High: $101.90M avg. 310.08% | Avg: $23.85M Low: $15.44M High: $40.70M avg. -60.05% |
FAQ
What is Cartesian Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 24.42% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -56.24M, average is -66.19M and high is -12.33M.
What is Cartesian Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 52.19% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $7.95M, average is $12.29M and high is $20.97M.
What is Cartesian Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 9.84% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$10.9, average is -$4.84 and high is $-2.39.
What is the best performing analyst?
In the last twelve months analysts have been covering Cartesian Therapeutics stock. The most successful analyst is John Newman.